Deacetylase Inhibitors Vorinostat or Panobinostat for Relapsed/Refractory Multiple Myeloma


Deacetylase Inhibitors Vorinostat or Panobinostat for Relapsed/Refractory Multiple Myeloma
Slides from presentations at ASH 2011 and transcribed comments from a recent interview with Paul G Richardson, MD (1/24/12)

Siegel DS et al. Vantage 095: Vorinostat in combination with bortezomib in salvage multiple myeloma patients: Final study results of a global Phase 2b trial. Proc ASH 2011;Abstract 480.

Richardson PG et al. Phase II study of the pan-deacetylase inhibitor panobinostat in combination with bortezomib and dexamethasone in relapsed and bortezomib-refractory multiple myeloma (PANORAMA 2). Proc ASH 2011;Abstract 814.

San-Miguel JF et al. Update on a Phase III study of panobinostat with bortezomib and dexamethasone in patients with relapsed multiple myeloma: PANORAMA 1. Proc ASH 2011;Abstract 3976.

Dr Richardson is Associate Professor of Medicine at Harvard Medical School and Clinical Director of the Jerome Lipper Center for Multiple Myeloma at Dana-Farber Cancer Institute in Boston, Massachusetts.